🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

18,54 USD

Máx. histórico

178,74

2142 días

Split 1:6 del 12/07/2012

Caída desde máximo

-89,63%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+1,20%

Cierre anterior

18,32

Rango de hoy

18,29 – 18,81

Volumen hoy

1.397.929

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,44%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 23 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
12/03/2001 29,25 30,00 24,75 25,50 -12,82% 17,95% 10.533
09/03/2001 30,94 30,94 28,50 29,25 -3,70% 7,88% 6.867
08/03/2001 32,81 33,38 30,00 30,38 -7,95% 10,29% 6.917
07/03/2001 34,13 34,13 32,25 33,00 -2,22% 5,49% 3.733
06/03/2001 33,75 34,13 33,38 33,75 +2,27% 2,22% 5.783
05/03/2001 31,88 33,38 31,69 33,00 +3,53% 5,29% 7.250
02/03/2001 33,00 34,50 30,75 31,88 -4,49% 11,36% 10.850
01/03/2001 33,84 34,13 33,19 33,38 -1,11% 2,77% 2.950
28/02/2001 34,88 35,25 33,75 33,75 -3,23% 4,30% 3.200
27/02/2001 36,00 36,75 34,88 34,88 -2,62% 5,21% 23.483
26/02/2001 34,13 36,00 33,94 35,81 +8,52% 6,04% 14.200
23/02/2001 32,53 33,38 32,25 33,00 -6,38% 3,46% 11.200
22/02/2001 34,50 35,25 32,44 35,25 +2,17% 8,15% 4.000
21/02/2001 36,75 39,09 34,50 34,50 -4,17% 12,50% 6.767
20/02/2001 37,41 37,50 36,00 36,00 +0,00% 4,01% 2.750
16/02/2001 35,53 37,50 34,88 36,00 -3,03% 7,39% 5.533
15/02/2001 34,88 37,50 34,50 37,13 +6,45% 8,60% 13.083
14/02/2001 35,25 35,25 34,13 34,88 +1,09% 3,19% 18.483
13/02/2001 36,47 37,13 34,31 34,50 -5,15% 7,71% 11.567
12/02/2001 35,63 37,50 35,06 36,38 +2,11% 6,84% 8.900
09/02/2001 37,88 38,25 35,06 35,63 -5,47% 8,42% 9.783
08/02/2001 38,91 39,38 37,69 37,69 -2,43% 4,34% 3.617
07/02/2001 39,38 40,13 38,63 38,63 -3,74% 3,81% 20.400
06/02/2001 40,13 40,88 39,38 40,13 -0,93% 3,74% 5.067
05/02/2001 41,81 41,81 40,50 40,50 -1,82% 3,14% 10.067
02/02/2001 40,78 42,38 40,50 41,25 +3,77% 4,60% 28.300
01/02/2001 39,28 40,50 39,19 39,75 -0,47% 3,34% 6.800
31/01/2001 40,88 42,00 39,94 39,94 +2,40% 5,05% 44.300
30/01/2001 38,63 39,38 37,88 39,00 +4,00% 3,88% 14.267
29/01/2001 34,69 42,00 34,50 37,50 +9,89% 21,62% 29.367